{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:32:24Z","timestamp":1793946744580,"version":"4.8.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22361132541"],"award-info":[{"award-number":["22361132541"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["24-45-00020"],"award-info":[{"award-number":["24-45-00020"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["25HB2711400"],"award-info":[{"award-number":["25HB2711400"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2025YFE0101400"],"award-info":[{"award-number":["2025YFE0101400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["CHN231114163506"],"award-info":[{"award-number":["CHN231114163506"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bmc.2026.118661","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T08:30:41Z","timestamp":1775896241000},"page":"118661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of novel 1,2,4-triazoles derivatives acting as NF1 activators against cervical cancer"],"prefix":"10.1016","volume":"138","author":[{"given":"Yao","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davor","family":"Margetic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijia","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Long","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118661_bb0005","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bmc.2026.118661_bb0010","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bmc.2026.118661_bb0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0140-6736(18)32470-X","article-title":"Cervical cancer","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2026.118661_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126177","article-title":"Assessing real world vaccine effectiveness: a review of scotlands approach to monitoring human papillomavirus (HPV) vaccine impact on HPV infection and cervical disease","volume":"42","author":"Cameron","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.bmc.2026.118661_bb0025","article-title":"Clinical outcomes and treatment efficacy in cervical cancer patients in the UAE: a retrospective cohort study","volume":"16","author":"Balaraj","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.bmc.2026.118661_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116715","article-title":"Novel tetrasubstituted 5-Arylamino pyrazoles able to interfere with angiogenesis and ca2+ mobilization","volume":"276","author":"Lusardi","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118661_bb0035","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1021\/acs.jmedchem.2c01612","article-title":"Indole derivatives as new structural class of potent and antiproliferative inhibitors of monocarboxylate transporter 1 (MCT1; SLC16A1)","volume":"66","author":"Puri","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118661_bb0040","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.70256","article-title":"New antiproliferative pyrazole\/quinoline hybrids: design, synthesis, and biological evaluation as EGFR inhibitors","volume":"107","author":"Shoman","year":"2026","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmc.2026.118661_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27185814","article-title":"Regioselective synthesis, structural characterization, and antiproliferative activity of novel tetra-substituted phenylaminopyrazole derivatives","volume":"27","author":"Lusardi","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2026.118661_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111697","article-title":"Potent combretastatin a-4 analogs containing 1,2,4-Triazole: synthesis, antiproliferative, anti-tubulin activity, and docking study","volume":"183","author":"Mustafa","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118661_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.864286","article-title":"Triazoles and their derivatives: chemistry, synthesis, and therapeutic applications","volume":"9","author":"Matin","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.bmc.2026.118661_bb0060","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2174\/1871520615666150819121106","article-title":"Recent developments on 1,2,4-Triazole nucleus in anticancer compounds: a review","volume":"16","author":"Kaur","year":"2016","journal-title":"Anti Cancer Agents Med Chem"},{"key":"10.1016\/j.bmc.2026.118661_bb0065","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1039\/C9MD00458K","article-title":"Application of triazoles as bioisosteres and linkers in the development of microtubule targeting agents","volume":"11","author":"Malik","year":"2020","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.bmc.2026.118661_bb0070","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/jhet.3258","article-title":"Analgesic and anti-inflammatory potential of merged pharmacophore containing 1,2,4-Triazoles and substituted benzyl groups via thio linkage","volume":"55","author":"Ahirwar","year":"2018","journal-title":"J Heterocyclic Chem"},{"key":"10.1016\/j.bmc.2026.118661_bb0075","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ejmech.2018.07.024","article-title":"Synthesis, anticancer activity and molecular modeling studies of 1,2,4-Triazole derivatives as EGFR inhibitors","volume":"156","author":"El-Sherief","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118661_bb0080","doi-asserted-by":"crossref","first-page":"7742","DOI":"10.1016\/j.bmc.2013.10.017","article-title":"Design, synthesis, and biological evaluation of 1,2,4-Triazole bearing 5-substituted Biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates","volume":"21","author":"Liu","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2026.118661_bb0085","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.bioorg.2018.08.031","article-title":"Synthesis, antimicrobial activity and molecular modeling study of 3-(5-Amino-1,2,4-triazol-3-yl)naphthyridinones as potential DNA-gyrase inhibitors","volume":"81","author":"Mohamed","year":"2018","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118661_bb0090","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.pharep.2018.06.007","article-title":"Synthesis and anticonvulsant screening of 1,2,4-Triazole derivatives","volume":"70","author":"Sari","year":"2018","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.bmc.2026.118661_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.135621","article-title":"Design, synthesis and molecular docking of 1,2,4-Triazole schiff base hybrids as tubulin, EGFR inhibitors and apoptosis-inducers","volume":"1286","author":"Mohamed","year":"2023","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmc.2026.118661_bb0100","article-title":"Mapk pathway inhibitors in thyroid cancer: preclinical and clinical data","volume":"15","author":"L.O.H.G.L.","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bmc.2026.118661_bb0105","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or Carboplatin\u2013Paclitaxel in Pulmonary Adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2026.118661_bb0110","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF v600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2026.118661_bb0115","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.bmc.2026.118661_bb0120","doi-asserted-by":"crossref","first-page":"9221","DOI":"10.1158\/0008-5472.CAN-08-1740","article-title":"Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR\/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235","volume":"68","author":"Eichhorn","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2026.118661_bb0125","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1038\/ncomms7377","article-title":"RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer","volume":"6","author":"Niederst","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2026.118661_bb0130","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2026.118661_bb0135","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrc3911","article-title":"A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumor suppressor","volume":"15","author":"Ratner","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2026.118661_bb0140","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2026.118661_bb0145","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmc.2026.118661_bb0150","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2013.03.002","article-title":"Lessons from the cancer genome","volume":"153","author":"Garraway","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2026.118661_bb0155","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/cbdv.200890199","article-title":"The biochemistry of drug metabolism\u2013an introduction: part 4. Reactions of conjugation and their enzymes","volume":"5","author":"Testa","year":"2008","journal-title":"Chem Biodivers"},{"key":"10.1016\/j.bmc.2026.118661_bb0160","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40242-017-6491-5","article-title":"A facile synthetic approach to 3-Halo-4-Substituted-1,5-Dihydro-4H-1,2,4-Triazoline-5-Thiones based on retro-Michael addition","volume":"33","author":"Tian","year":"2017","journal-title":"Chem Res Chin Univ"},{"key":"10.1016\/j.bmc.2026.118661_bb0165","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.molstruc.2018.08.104","article-title":"Synthesis of 4,6-Disubstituted pyrazolo[3,4-d]pyrimidine analogues: cyclin-dependent kinase 2 (CDK2) inhibition, molecular docking and anticancer evaluation","volume":"1176","author":"Cherukupalli","year":"2019","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmc.2026.118661_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117284","article-title":"Design, synthesis, and biological evaluation of imidazolidinone derivatives as potent PPAR\u03b1\/\u03b4 agonists for the treatment of cholestatic liver diseases","volume":"286","author":"Fu","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118661_bb0175","article-title":"Copper-catalyzed substrate-controlled carbonylative synthesis of \u03b1-keto amides and amides from alkyl halides","volume":"61","author":"Zhao","year":"2022","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmc.2026.118661_or0005","doi-asserted-by":"crossref","unstructured":"(a) Suleyman, A.; Nebih, L.; Hatice, E. D.; et al. Design and synthesis of 4-arylazo pyrazole carboxamides as dual AChE\/BChE inhibitors: kinetic and in silico evaluation. Pharmaceuticals 2026, 19, 239.","DOI":"10.3390\/ph19020239"},{"key":"10.1016\/j.bmc.2026.118661_or0010","doi-asserted-by":"crossref","unstructured":"(b) \u00d6zcan, G.; Hatice, E. D.; Mustafa, A.; et al. Chalcone-inspired indole, carbazole, and phenothiazine hybrids as potent aldose reductase inhibitors with selective anticancer potential: rational design, synthesis, and multi-level characterization. Bioorg Chem 2025, 164, 108861.","DOI":"10.1016\/j.bioorg.2025.108861"},{"key":"10.1016\/j.bmc.2026.118661_or0015","doi-asserted-by":"crossref","unstructured":"(c) Med Chem Commun 2025, DOI: https:\/\/doi.org\/10.1039\/D4MD00617H.","DOI":"10.1039\/D4MD00617H"},{"key":"10.1016\/j.bmc.2026.118661_or0020","doi-asserted-by":"crossref","unstructured":"(d) Blinera, Z.; Arleta, R. N.; Hatice, E. D.; et al. N-substituted phthalimide\u2013carboxylic acid hybrids as dual-targeted aldose reductase inhibitors: synthesis, mechanistic insights, and cancer-relevant profiling. Bioorg Chem 2025, 163, 108788.","DOI":"10.1016\/j.bioorg.2025.108788"},{"key":"10.1016\/j.bmc.2026.118661_or0025","doi-asserted-by":"crossref","unstructured":"(e) Dafina, H.; Arleta, R. N.; Hatice, E. D.; et al. Phthalimide\u2013benzoic acid hybrids as potent aldose reductase inhibitors: synthesis, enzymatic kinetics, and in silico characterization. Bioorg Med Chem 2025, 131, 118416.","DOI":"10.1016\/j.bmc.2025.118416"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:00:50Z","timestamp":1793944850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626001173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":40,"alternative-id":["S0968089626001173"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118661","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel 1,2,4-triazoles derivatives acting as NF1 activators against cervical cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118661","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118661"}}